2013•Anti-Cancer Agents in Medicinal ChemistryRequires access

Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer

M.J. Molina-Garrido, Carmen Guillén‐Ponce, A. Mora-Rufete

Abstract

Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items. Keywords: Adjuvant Online, aging, anit-HER2 therapy, breast cancer, cardiotoxicity, chemotherapy, comorbidity, Comprehensive Geriatric Assessment, elderly women, histology, HER2 positive, lapatinib, St Gallen criteria, targeted therapy, trastuzumab.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lapatinib, Trastuzumab, Medicine, Oncology, Breast cancer, Internal medicine, Metastatic breast cancer, Cancer